加载中
NASDAQHealthcareMedical - Instruments & Supplies
最新数据
US$26.91
−US$0.07 · -0.26%
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.
前收盘价
US$26.91
−US$0.07 · -0.26%
盘后
US$26.91
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.
日内区间
当前US$26.91
52周区间
当前US$26.91
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
62
低估
情绪
41
多空交织
风险
45
风险偏高
动量
64
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.
日内区间
当前US$26.91
52周区间
当前US$26.91
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2026财年 | 2025财年 | 2024财年 | 2023财年 |
|---|---|---|---|---|
| 营收 | 9512.7万 USD | 5981.5万 USD | 2781.4万 USD | 763万 USD |
| 销货成本 | 4626.3万 USD | 3560.5万 USD | 2745.2万 USD | 1828.1万 USD |
| 毛利 | 4886.4万 USD | 2421万 USD | 36.2万 USD | −1065.1万 USD |
| 研究与开发 | 1948.3万 USD | 1565.2万 USD | 1549万 USD | 1575.6万 USD |
| 销售、一般及管理费用 | 1.64亿 USD | 1.15亿 USD | 6993.5万 USD | 5401.4万 USD |
| 营业费用 | 1.84亿 USD | 1.31亿 USD | 8542.5万 USD | 6977万 USD |
| 利息收入 | 835.1万 USD | 319.9万 USD | — | — |
| 利息支出 | 754.7万 USD | 773.4万 USD | 623万 USD | 562.9万 USD |
| 折旧和摊销 | 870.9万 USD | 796.8万 USD | 1156万 USD | 485.5万 USD |
| 营业利润 | −1.35亿 USD | −1.06亿 USD | −8506.3万 USD | −8042.1万 USD |
| 净利润 | −1.32亿 USD | −1.14亿 USD | −9412万 USD | −8423.8万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$30.67
上涨空间 13.97%评级样本有限，仅4项
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2387.51万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM1895.34万0.02%787.4亿 USD0.19%US$277.9-0.37%
iShares Russell 2000 Growth ETFIWO659.98万0.05%139.17亿 USD0.24%US$353.71-0.86%
First Trust Small Cap Growth AlphaDEX FundFYC652.54万0.48%13.49亿 USD0.70%US$114.85-0.44%
Vanguard Extended Market ETFVXF580.92万0.01%954亿 USD0.05%US$233.52-0.63%
Schwab U.S. Small-Cap ETFSCHA471.99万0.02%217.13亿 USD0.03%US$32.66-0.40%
iShares U.S. Medical Devices ETFIHI438.36万0.12%35.74亿 USD0.37%US$52.79+2.03%
Vanguard Russell 2000 ETFVTWO396.62万0.02%180亿 USD0.06%US$112.27-0.35%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOFirst Trust Small Cap Growth AlphaDEX FundFYCVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHAiShares U.S. Medical Devices ETFIHIVanguard Russell 2000 ETFVTWOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
